Molecular Immunologic & Translational Sciences (MITS) Core

Our Facility


The MITS Core offers a nexus of expertise and equipment to serve UVA biomedical researchers in the studies of cancer in human-derived materials and animal models with a suite of cellular, molecular and preclinical protocols as well as analytical techniques to evaluate the impact of investigational agents on the diagnosis or treatment of cancer.  


Our facility exists to enhance the scope and quality of scientific cancer research performed at UVA, and is an integral part of the UVA translational and innovation research initiatives. 

To that end the Cancer Center Support Grant (CCSG) currently provides a 10% co-pay on MITS services for all its Cancer Center investigators. This co-pay may vary throughout the fiscal year.  Investigators who receive this financial assistance for core services should acknowledge both CCSG grant number 2P30CA044579-26 and the UVA MITS Core Facility services and equipment in all publications. 

Acknowledgement is vital to the Cancer Center Support Grant renewal and is used as a value based metric in determining future funding.


Recent Publications - Authorship and Core Acknowledgements

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.  Victor H Englehard, Rebecca C Obeng, Kara L Cummings, Gina R Petroni, Angela L Ambakhutwala, Kimberly A Chianese-Bullock, Kelly T Smith, Amanda Lulu, Nikole Varhegy, Mark E Smolkin, Paisley Myers, Keira E Mahoney, Jeffrey Shabanowitz, Nico Buettner, Emily H Hall, Kathleen Haden, Mark Cobbold, Donald F Hunt, Geoffrey Weiss, Elizabeth Gaughan, Craig L Slingluff Jr  Journal for ImmunoTherapy of Cancer Volume 8, Issue 1 (2020)  Read Article

Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation. TT Wang, J Yang, S Dighe, MW Schmachtenberg, NT Leigh, E Farber, S Onengut-Gumuscu, DJ Feith, A Ratan, TP Loughran, and TL Olson. Cancers, 2020 12(1), 126  Read Article

Deletion of the SAPS1 subunit of protein phosphatase 6 in mice increases radiosensitivity and impairs the cellular DNA damage response. Jaroslaw Dziegielewski, Magdalena A. Bońkowska, Ewa A. .Poniecka, Jinho Heo, Kangping Du, Rowena B. Crittenden, Timothy P. Bender, David L. Brautigan, James M. Larner. DNA Repair Vol 85, January 2020  Read Article

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients.  Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadeida V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan & Craig L. Slingluff Jr.
Journal for ImmunoTherapy of Cancer volume 7, Article number: 163 (2019)  Read Article